Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Krebs, I; Vécsei Marlovits, V; Bodenstorfer, J; Glittenberg, C; Ansari Shahrezaei, S; Ristl, R; Binder, S.
Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.
Acta Ophthalmol. 2013; 91(3):e178-e183 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Ansari Shahrezaei Siamak
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Modern therapy of neovascular age-related macular degeneration consists in intravitreal injections of inhibitors of the vascular endothelial growth factor. An increasing number of these injections is required not only in monthly but also in as-needed treatment regimen. In this study, it should be examined whether an additional administered photodynamic therapy (PDT) can considerably reduce the number of injection. In this prospective, randomized study carried out in three large hospitals of Vienna eyes with neovascular age-related macula degeneration were included. Patients were randomized to either Ranibizumab monotherapy or combined standard fluence PDT and Ranibizumab therapy. All patients received a loading dose of three intravitreal Ranibizumab injections and were thereafter treated in an as-needed regimen based on distance acuity and retinal thickness values. In the combined treatment group, PDT was administered 1 day after the first Ranibizumab injection. Fifty-one patients were randomized, 44 were finally included (four screening failures and three withdrawals). Twenty-four patients were assigned to the monotherapy and 20 patients to the combined treatment group. Fewer injections were required in the combined treatment group (4.7 versus 6.3). Overall the patients lost 0.5 letters; in the combined treatment group, the patients lost mean 7.1 letters; in the monotherapy group, they gained mean 5.1 letters. Retinal thickness decreased significantly in both groups. A significant reduction of the number of required intravitreal injections could be achieved by the additional PDT treatment, but was accompanied by a worse functional outcome in this group. © 2012 The Authors. Acta Ophthalmologica © 2012 Acta Ophthalmologica Scandinavica Foundation.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Aged, 80 and over -
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Combined Modality Therapy -
Female -
Fluorescein Angiography -
Humans -
Intravitreal Injections -
Male -
Microscopy, Acoustic -
Middle Aged -
Photochemotherapy -
Photosensitizing Agents - therapeutic use
Porphyrins - therapeutic use
Prospective Studies -
Ranibizumab -
Retreatment -
Tomography, Optical Coherence -
Treatment Outcome -
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity - physiology
Wet Macular Degeneration - diagnosis
Wet Macular Degeneration - drug therapy
Wet Macular Degeneration - physiopathology

Find related publications in this database (Keywords)
age-related macular degeneration
choroidal neovascularization
photodynamic therapy (Verteporfin (R))
Ranibizumab (Lucentis (R))
vascular endothelial growth factor
© Meduni Graz Impressum